The Jafral biotechnology company was created in response to the pressing problem of increasing bacterial resistance to antibiotics, resulting in 25.000 deaths each year in Europe alone. Antibiotic resistance represents a major expense in industries such as agriculture, nutrition and veterinary medicine, with bacteriophages or virus-destroying bacteria, being the most promising alternative to antibiotics.
In addition to producing bacteriophage material on request, Jafral also offers an independent development of the production process for a specific bacteriophage. Its first bacteriophage test material has been used for research purposes to treat bacterial infections in implants that are substitutes for amputated limbs.
In 2012, Jafral was the finalist for Slovenian Startup of the Year award!